What is the recommended tetanus-diphtheria (Td) or tetanus-diphtheria-pertussis (Tdap) vaccination series and booster schedule, including dose, frequency, route, duration, and side effects, for a patient with no prior tetanus immunizations who presents with an animal bite?

Tetanus Vaccination for Animal Bite in Unvaccinated Patients

For a patient with no prior tetanus immunizations presenting with an animal bite, initiate a 3-dose primary series with Tdap as the first dose (0.5 mL IM in the deltoid), followed by Td at >4 weeks, and a third Td dose at 6-12 months; additionally, administer Tetanus Immune Globulin (TIG) 250 units IM at a separate site if the wound is not clean and minor. 1

Primary Vaccination Series for Unvaccinated Adults

Dose and Schedule

• First dose: Tdap 0.5 mL intramuscularly (IM), preferably in the deltoid muscle 2
• Second dose: Td 0.5 mL IM, administered >4 weeks after the first dose 1
• Third dose: Td 0.5 mL IM, administered 6-12 months after the second dose 1, 3

The preferred schedule prioritizes Tdap first to provide pertussis protection, though Tdap can substitute for any of the three doses in the primary series 1. This is critical because adults with unknown or uncertain vaccination histories should be considered to have had no previous tetanus toxoid-containing vaccine 1.

Route of Administration

All doses are administered intramuscularly, with the deltoid muscle being the preferred site for persons aged ≥7 years 2. For children aged ≤2 years (if applicable), the anterolateral thigh is preferred 2.

Wound Management Considerations

When to Give TIG (Tetanus Immune Globulin)

For patients with incomplete or unknown vaccination history (<3 documented doses):

• Clean, minor wounds: Tdap/Td only; no TIG needed 3
• All other wounds (contaminated with dirt, feces, soil, saliva; puncture wounds; avulsions; crush injuries; burns): Both Tdap/Td AND TIG 250 units IM 1, 3

Critical point: When both TIG and tetanus toxoid-containing vaccine are indicated, administer each product using separate syringes at different anatomic sites 1, 3. This prevents interference with active immunization.

Wound Classification

"All other wounds" include those contaminated with dirt, feces, soil, or saliva; puncture wounds; avulsions; wounds from missiles, crushing, burns, and frostbite 3. Animal bites typically fall into this category and warrant both active and passive immunization in unvaccinated individuals.

Subsequent Booster Schedule

After completing the 3-dose primary series:

• First booster: 10 years after the third dose 4, 5
• Routine boosters: Every 10 years thereafter 2, 5

A practical approach is to vaccinate at mid-decade ages (25,35,45 years, etc.) to ensure compliance 4. The 2020 ACIP update allows either Td or Tdap for decennial boosters, increasing flexibility 5.

For Future Wounds

Once the primary series is complete:

• If wound occurs <5 years after last dose: No booster needed for any wound type 3
• If wound occurs 5-10 years after last dose: Booster needed only for non-clean, non-minor wounds 3
• If wound occurs >10 years after last dose: Booster needed for all wounds 3

Side Effects and Adverse Reactions

Common Local Reactions

• Erythema and induration at injection site, with or without tenderness 4
• Pain at injection site (most common) 2
• Swelling at injection site 6, 7

Local reactions are generally mild and self-limited. Studies show that shorter intervals between doses (even <2 years) may slightly increase local reactions but do not cause serious adverse events 6, 7.

Systemic Reactions

• Fever (less common than local reactions) 4
• Malaise 4
• Generalized symptoms are uncommon 8

Rare but Serious Reactions

• Arthus-type hypersensitivity reactions: Severe local reactions starting 2-8 hours post-injection, often with fever and malaise, particularly in those with multiple prior boosters 4. If this occurs, defer tetanus toxoid-containing vaccines for >10 years 1
• Generalized urticaria or anaphylaxis: Extremely rare 4
• Neurologic complications: Rarely reported, causal relationship not established 4

Safety Profile

The overall safety profile of Tdap is similar to Td vaccine 9, 8. No serious adverse events, whole limb swelling, or Arthus-like reactions were reported in large safety studies 6. Repeated Tdap vaccination has acceptable safety 10.

Important Clinical Pitfalls

Do Not Delay Vaccination

When Tdap is indicated (including for wound management), administer it regardless of the interval since the last tetanus or diphtheria toxoid-containing vaccine 2. The benefits of pertussis protection outweigh the potential risk of increased local reactions 2.

Verify Vaccination History Carefully

Do not assume protection based on patient recall alone. Ascertaining the interval since the most recent dose is insufficient—determine the total number of doses received 4. Persons with unknown or uncertain histories should be considered unvaccinated 1, 4.

Pregnancy Considerations

Although not directly relevant to the animal bite scenario, pregnant women should receive Tdap during each pregnancy (27-36 weeks' gestation), regardless of prior Tdap history 2. For wound management in pregnant women who previously received Tdap, Tdap is still preferred over Td 5.

Product Selection

• Boostrix: Approved for ages ≥10 years 2
• Adacel: Approved for ages 10-64 years 2
• For adults ≥65 years, Boostrix is preferred, but either product is acceptable 2

Contraindications

A history of severe hypersensitivity reaction (generalized urticaria or anaphylaxis) or neurologic reaction after a previous dose is a contraindication 4. However, local side effects alone do not preclude continued use 4.